Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Profit After Tax (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Profit After Tax for 13 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 128.47% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.3 million, a 158.88% increase, with the full-year FY2024 number at -$15.5 million, up 71.87% from a year prior.
  • Profit After Tax was $3.6 million for Q3 2025 at Theravance Biopharma, down from $54.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $54.8 million in Q2 2025 to a low of -$86.5 million in Q1 2021.
  • A 5-year average of -$19.1 million and a median of -$15.6 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 41.88% in 2024, then soared 431.75% in 2025.
  • Theravance Biopharma's Profit After Tax stood at -$35.3 million in 2021, then soared by 64.68% to -$12.5 million in 2022, then rose by 28.23% to -$9.0 million in 2023, then crashed by 73.49% to -$15.5 million in 2024, then skyrocketed by 123.28% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Profit After Tax are $3.6 million (Q3 2025), $54.8 million (Q2 2025), and -$13.6 million (Q1 2025).